Palliative care medicines: see Palliative care section
- Comprehensive and useful list of all national medication related Covid guidance. SEL CCG workbook signposting to national clinical guidance through NICE and SPS to support healthcare professionals during COVID-19 pandemic
- Blood monitoring for patients with LTCs
Priority patients that will gain most benefit:
- at risk of a serious adverse drug event that can be identified through monitoring
- taking a Narrow Therapeutic Index drug during a phase when intensive monitoring is still required (e.g. upon initiation)
- have recently had an illness that may have impacted on how their drug works
Structured Medication Review
Structured Medication Review for Diabetes Webinar – 19 August 2020
Mental health structured medication review webinar – 13 August 2020
MHRA: no concern with COVID. Do not stop
- National guidance. Includes advice on management of patients taking warfarin in primary care during the Covid-19 pandemic, with recommendations to help minimise attendances
- Switching from warfarin to DOACs
During infection: assess on case by case basis if hypotensive.
Chloroquine and hydroxychloroquine
Roll out of Electronic Prescription Service (EPS) Phase 4
The supply of illicit drugs into the UK has reduced significantly and will continue to reduce further. The result of this is that street prices of illicit drugs are rising, and their quality is diminishing. The illicit trade in prescription medication such as diazepam and pregabalin is increasing with reports that prices have already doubled.
To prevent the levels of theft that are likely to seriously affect operational effectiveness and the safety of all staff at this most critical time, organisations should urgently review their current security arrangements.
Asthma patients should continue inhalers and medication as normal.
Multi Compartment Aids
Pharmacological management of Adult non-cancer chronic pain
- Advice for Rheumatology patients on immunosuppressant medication
- Osteoporosis: Interim guidance has been developed to support prescribing and administration of the next dose of denosumab (Prolia™) in primary care during the pandemic and recovery phase. This is a temporary arrangement to support continuity of patient care during the pandemic/recovery phase for patients with osteoporosis currently receiving denosumab (Prolia™) from local secondary care services.